RedHill Biopharma (RDHL) Liabilities and Shareholders Equity (2011 - 2025)

RedHill Biopharma (RDHL) has reported Liabilities and Shareholders Equity for 15 consecutive years, with $25.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 40.47% year-over-year to $25.3 million; the TTM figure through Dec 2025 stood at $83.8 million (down 14.63% YoY), while the FY2025 annual figure was $25.3 million, up 40.47% from the prior year.
• Liabilities and Shareholders Equity advanced to $25.3 million in Q4 2025 per RDHL's latest filing, from $18.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $220.1 million in Q1 2021 and bottomed at $18.0 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $109.5 million across 5 years, with a median of $157.2 million in 2022.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 53.42% — and 2023, when it tumbled 85.49%.
• RedHill Biopharma's Liabilities and Shareholders Equity stood at $181.2 million in 2021, then fell by 12.32% to $158.9 million in 2022, then sank by 85.49% to $23.0 million in 2023, then retreated by 21.71% to $18.0 million in 2024, then soared by 40.47% to $25.3 million in 2025.
• Business Quant data shows RDHL's Liabilities and Shareholders Equity at $25.3 million in Q4 2025, $18.4 million in Q2 2025, and $18.0 million in Q4 2024.